Rhumbline Advisers Magenta Therapeutics, Inc. Transaction History

Rhumbline Advisers

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.97 - $3.08 $24,279 - $77,092	-25,030 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.55 - $5.23 $1,150 - $2,358	451 Added 1.83%	25,030 $73,000
Q4 2021 Feb 10, 2022	SELL	$4.43 - $8.33 $748 - $1,407	-169 Reduced 0.68%	24,579 $109,000
Q3 2021 Nov 12, 2021	SELL	$6.07 - $9.89 $12,364 - $20,145	-2,037 Reduced 7.61%	24,748 $180,000
Q2 2021 Aug 05, 2021	BUY	$9.76 - $14.15 $20,066 - $29,092	2,056 Added 8.31%	26,785 $262,000
Q1 2021 May 06, 2021	SELL	$7.66 - $13.38 $4,864 - $8,496	-635 Reduced 2.5%	24,729 $293,000
Q4 2020 Feb 10, 2021	BUY	$6.1 - $7.94 $32,756 - $42,637	5,370 Added 26.86%	25,364 $199,000
Q3 2020 Nov 12, 2020	SELL	$6.52 - $8.94 $10,823 - $14,840	-1,660 Reduced 7.67%	19,994 $136,000
Q2 2020 Aug 13, 2020	SELL	$6.18 - $10.76 $1,915 - $3,335	-310 Reduced 1.41%	21,654 $163,000
Q4 2019 Feb 05, 2020	BUY	$9.07 - $15.84 $1,659 - $2,898	183 Added 0.84%	21,964 $333,000
Q3 2019 Oct 23, 2019	SELL	$9.63 - $14.0 $1,926 - $2,800	-200 Reduced 0.91%	21,781 $223,000
Q2 2019 Aug 14, 2019	BUY	$13.4 - $17.67 $88,962 - $117,311	6,639 Added 43.27%	21,981 $324,000
Q1 2019 May 01, 2019	BUY	$5.7 - $19.7 $87,449 - $302,237	15,342 New	15,342 $253,000

442K

Ticker MGTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,890,500
Description
Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops medicines to bring the curative power of stem cell transplants to patients with blood cancers, genetic diseases, and autoimmune diseases. It develops MGTA-117, an anti-CD117 antibody that targets hematopoietic stem cells (HSCs) and genetically mutated stem cells that ca...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.